VIM and prostate cancer: uPA, a serine protease with multiple function, acts as risk assessment and a possible treatment target in many cancers,[10,17,18] such as breast cancer,[9,19,20] pancreatic cancer,[21,22] prostate cancer,[23,24] and ovarian cancer.[25–27] In particular, uPA can accelerate tumor metastasis and promote tumor angiogenesis by degrading extracellular matrix (ECM) and basement membranes, such as vimentin and fibronectin, involving in epithelial-mesenchymal transition (EMT).[27,28] Moreover, international guidelines (AGO, St.